In vivo experiments results showed that YCHT could significantly reduce mice liver injury and hepatic steatosis, and mice liver tissue RNA-seq transcriptome sequencing results showed that the mechanism of YCHT prevention and treatment of AFLD was most related to the PPAR-mediated fatty acid metabolism signaling pathway. This evidence concerns the gene PPARA and Hepatic steatosis.